The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Short-acting β2-agonist prescriptions in patients with asthma: findings from the South Korean cohort of SABINA III

  • Kwang-Ha Yoo (Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine) ;
  • Sang-Ha Kim (Department of Internal Medicine, Yonsei University Wonju College of Medicine) ;
  • Sang-Heon Kim (Department of Internal Medicine, Hanyang University College of Medicine) ;
  • Ji-Yong Moon (Department of Internal Medicine, Hanyang University College of Medicine) ;
  • Heung-Woo Park (Department of Internal Medicine, Seoul National University Hospital) ;
  • Yoon-Seok Chang (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Maarten J.H.I Beekman (AstraZeneca)
  • Received : 2023.02.23
  • Accepted : 2023.08.11
  • Published : 2024.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background/Aims: Despite short-acting β2-agonist (SABA) overuse being associated with poor asthma outcomes, data on SABA use in South Korea is scarce. Herein, we describe prescription patterns of SABA and other asthma medications in patients from the South Korean cohort of the SABA use IN Asthma (SABINA) III study. Methods: This study included patients with asthma aged ≥ 12 years, who had ≥ 3 consultations with the same healthcare provider, and medical records containing data for ≥ 12 months prior to the study visit. Patients were classified by investigator-defined asthma severity (per 2017 Global Initiative for Asthma recommendations) and practice type (primary or specialist care). Data on disease characteristics, asthma treatments, and clinical outcomes in the 12 months before the study visit were collected using electronic case report forms. Results: Data from 476 patients (mean age, 55.4 years; female, 63.0%) were analyzed. Most patients were treated by specialists (83.7%) and had moderate-to-severe asthma (91.0%). Overall, 7.6% of patients were prescribed ≥ 3 SABA canisters (defined as over-prescription). In patients prescribed SABA in addition to maintenance therapy, 47.4% were over-prescribed SABA. Most patients (95.4%) were prescribed a fixed-dose combination of an inhaled corticosteroid and a long-acting β2-agonist as maintenance therapy. Although asthma was well-controlled/partly-controlled in 91.6% of patients, 29.6% experienced ≥ 1 severe asthma exacerbation. Conclusions: SABA over-prescription was reported in nearly 50% of patients prescribed SABA in addition to maintenance therapy, underscoring the need to align clinical practices with the latest evidence-based recommendations and educate physicians and patients on appropriate SABA use.

Keywords

Acknowledgement

Medical writing and editorial support were provided by Tejaswini Subbannayya, PhD, of Cactus Life Sciences (part of Cactus Communications, Mumbai, India), in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3), which was fully funded by AstraZeneca.

References

  1. Global Asthma Network. The Global Asthma Report 2018 [Internet]. Auckland: Global Asthma Network, c2018 [cited 2023 May 26]. Available from: http://globalasthmareport.org/2018/.
  2. Lee E, Kim A, Ye YM, Choi SE, Park HS. Increasing prevalence and mortality of asthma with age in Korea, 2002-2015: a nationwide, population-based study. Allergy Asthma Immunol Res 2020;12:467-484. https://doi.org/10.4168/aair.2020.12.3.467
  3. National Health Insurance Service. National health insurance statistical yearbook [Internet]. Daejeon: Statistics Korea, c2022 [cited 2023 Jan 16]. Available from: https://kosis.kr/statHtml/statHtml.do?orgId=350&tblId=TX_35001_A061&language=en&conn_path=I3.
  4. Demoly P, Annunziata K, Gubba E, Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev 2012;21:66-74. https://doi.org/10.1183/09059180.00008111
  5. Dhar R, Ip M, Kulkarni T, et al. Challenges faced in managing adult asthma: a perspective from Asian countries. Respirology 2020;25:1235-1242. https://doi.org/10.1111/resp.13935
  6. Price D, David-Wang A, Cho SH, et al. Time for a new language for asthma control: results from REALISE Asia. J Asthma Allergy 2015;8:93-103.
  7. O'Byrne PM, Jenkins C, Bateman ED. The paradoxes of asthma management: time for a new approach? Eur Respir J 2017;50:1701103.
  8. Bloom CI, Cabrera C, Arnetorp S, et al. Asthma-related health outcomes associated with short-acting β2-agonist inhaler use: an observational UK study as part of the SABINA global program. Adv Ther 2020;37:4190-4208. https://doi.org/10.1007/s12325-020-01444-5
  9. Nwaru BI, Ekstrom M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J 2020;55:1901872.
  10. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2023 update [Internet]. Fontana (WI): Global Initiative for Asthma, c2023 [cited 2023 Jun 16]. Available from: https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full-Report-2023-WMS.pdf.
  11. National Health Insurance Service. Health security system [Internet]. Wonju: National Health Insurance Service, c2020 [cited 2023 Jan 16]. Available from: https://www.nhis.or.kr/english/wbheaa02300m01.do.
  12. Lee H, Ryu J, Chung SJ, et al. Short-acting beta2-agonist use in asthma in Korea: a 10-year population-based study. Allergy Asthma Immunol Res 2021;13:945-953. https://doi.org/10.4168/aair.2021.13.6.945
  13. Cabrera CS, Nan C, Lindarck N, Beekman MJHI, Arnetorp S, van der Valk RJP. SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting β2-agonist use in asthma. Eur Respir J 2020;55:1901858.
  14. Janson C, Menzies-Gow A, Nan C, et al. SABINA: an overview of short-acting β2-agonist use in asthma in European countries. Adv Ther 2020;37:1124-1135. https://doi.org/10.1007/s12325-020-01233-0
  15. Bateman ED, Price DB, Wang HC, et al. Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. Eur Respir J 2022;59:2101402.
  16. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2017 update [Internet]. Fontana (WI): Global Initiative for Asthma, c2017 [cited 2023 Jan 16]. Available from: https://ginasthma.org/wp-content/uploads/2019/04/wmsGINA-2017-main-report-final_V2.pdf.
  17. World Health Organization. Regional Office for the Western Pacific. The Asia-Pacific perspective: redefining obesity and its treatment [Internet]. Sydney: Health Communications Australia, c2000 [cited 2023 Jan 16]. Available from: https://apps.who.int/iris/handle/10665/206936.
  18. Reddel HK, Taylor DR, Bateman ED, et al.; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59-99. https://doi.org/10.1164/rccm.200801-060ST
  19. Choi JY, Yoon HK, Lee JH, et al. Current status of asthma care in South Korea: nationwide the Health Insurance Review and Assessment Service database. J Thorac Dis 2017;9:3208-3214. https://doi.org/10.21037/jtd.2017.08.109
  20. Jo EJ, Kim MY, Kim SH, et al. Implementation of asthma management guidelines and possible barriers in Korea. J Korean Med Sci 2020;35:e72.
  21. Cho EY, Oh KJ, Rhee CK, et al. Comparison of clinical characteristics and management of asthma by types of health care in South Korea. J Thorac Dis 2018;10:3269-3276. https://doi.org/10.21037/jtd.2018.05.95
  22. Korean Legislation Research Institute. Pharmaceutical affairs acts [Internet]. Sejong: Korean Legislation Research Institute, c2017 [cited 2023 Jan 16]. Available from: https://elaw.klri.re.kr/eng_service/lawView.do?hseq=40196&lang=ENG.
  23. Kim S, Kim J, Kim K, et al. Healthcare use and prescription patterns associated with adult asthma in Korea: analysis of the NHI claims database. Allergy 2013;68:1435-1442. https://doi.org/10.1111/all.12256
  24. Choi JY, Yoon HK, Lee JH, et al. Nationwide use of inhaled corticosteroids by South Korean asthma patients: an examination of the Health Insurance Review and Service database. J Thorac Dis 2018;10:5405-5413. https://doi.org/10.21037/jtd.2018.08.110
  25. Kim SR, Lee YC, Sung MJ, Bae HW. Current epidemiological data on asthma management in South Korea from qualitative assessment of asthma management by Health Insurance Review and Assessment Service (HIRA). Tuberc Respir Dis (Seoul) 2017;80:221-225. https://doi.org/10.4046/trd.2017.80.3.221
  26. Price D, Castro M, Bourdin A, Fucile S, Altman P. Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety. Eur Respir Rev 2020;29:190151.
  27. Thompson PJ, Salvi S, Lin J, et al. Insights, attitudes and perceptions about asthma and its treatment: findings from a multinational survey of patients from 8 Asia-Pacific countries and Hong Kong. Respirology 2013;18:957-967. https://doi.org/10.1111/resp.12137
  28. Chin MC, Sivasampu S, Khoo EM. Prescription of oral short-acting beta 2-agonist for asthma in non-resource poor settings: a national study in Malaysia. PLoS One 2017;12:e0180443.
  29. Tan NC, Tay IH, Ngoh A, Tan M. Factors influencing family physicians' drug prescribing behaviour in asthma management in primary care. Singapore Med J 2009;50:312-319.
  30. Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007;61:725-736. https://doi.org/10.1111/j.1742-1241.2007.01338.x
  31. Rabe KF, Pizzichini E, Stallberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006;129:246-256. https://doi.org/10.1378/chest.129.2.246
  32. O'Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med 2018;378:1865-1876. https://doi.org/10.1056/NEJMoa1715274
  33. Boulet LP, Phillips R, O'Byrne P, Becker A. Evaluation of asthma control by physicians and patients: comparison with current guidelines. Can Respir J 2002;9:417-423. https://doi.org/10.1155/2002/731804
  34. Baddar S, Jayakrishnan B, Al-Rawas O, George J, Al-Zeedy K. Is clinical judgment of asthma control adequate?: a prospective survey in a tertiary hospital pulmonary clinic. Sultan Qaboos Univ Med J 2013;13:63-68. https://doi.org/10.12816/0003197
  35. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med 2014;24:14009.
  36. Organisation for Economic Co-operation and Development (OECD). OECD Reviews of Public Health: Korea. A Healthier Tomorrow. Paris: OECD Publishing, 2020.